Health & Fitness

According to FutureWise analysis the market for Metastatic Bone Disease Treatment in 2026 is US$ 18.04 billion, and is expected to reach US$ 36.28 billion by 2036 at a CAGR of 7.24%. The growth in metastatic bone disease treatment is fueled by rising advanced-stage cancer cases and the demand for effective pain management. Innovations in targeted therapies, radiopharmaceuticals, and combination treatments enhance patient outcomes. Moreover, early diagnosis and multidisciplinary care are expanding treatment options globally. Metastatic Bone Disease (MBD) treatment is a crucial aspect of oncology care, focusing on the management of cancer that has spread from its original site to the bones. Bones are among the most common sites for metastasis, particularly in cancers such as breast, prostate, lung, kidney, and multiple myeloma. When cancer cells invade the bone tissue, they disrupt normal bone remodeling processes, leading to complications like severe pain, fractures, spinal cord ... Continue reading →

According to FutureWise analysis the market for metered dose inhalers in 2026 is US$ 21.44 billion, and is expected to reach US$ 38.26 billion by 2036 at a CAGR of 5.96%. Growth in market is fueled by increasing respiratory disorders like asthma and COPD, along with rising air pollution and smoking rates. Technological advancements in inhaler design, such as dose counters and improved formulations, enhance treatment adherence and efficiency. Moreover, greater access to these therapies in emerging markets and supportive healthcare policies contribute to market expansion. Metered dose inhalers (MDIs) are essential drug delivery devices primarily used in the management of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). These devices are designed to deliver a precise and consistent dose of medication directly into the lungs, facilitating rapid symptom relief and long-term control of the disease. Their compact size and portability, along with their ... Continue reading →

According to FutureWise analysis the market for metformin hydrochloride api in 2026 is US$ 0.38 billion, and is expected to reach US$ 0.63 billion by 2036 at a CAGR of 4.91%. The growth of the metformin hydrochloride API market is fueled by the rising global prevalence of type 2 diabetes and the demand for cost-effective antidiabetic therapies. Metformin remains a key component in oral diabetes medications due to its efficacy, safety, and regulatory acceptance. Additionally, increased generic drug production and demand from emerging markets contribute to this steady growth. Metformin hydrochloride is an active pharmaceutical ingredient (API) that serves as a key component in the production of one of the most widely prescribed oral antidiabetic medications in the world. It is primarily utilized as a first-line treatment for type 2 diabetes mellitus, playing a crucial role in managing blood glucose levels. Metformin works by enhancing insulin sensitivity, reducing the production of ... Continue reading →

According to FutureWise analysis the market for methymalonic acidemia in 2026 is US$ 10.04 billion, and is expected to reach US$ 16.10 billion by 2036 at a CAGR of 4.84%. The growth of the methylmalonic acidemia market is driven by increased awareness of rare metabolic disorders, enhanced newborn screening, and advancements in diagnostics. Targeted therapies, gene-based treatments, and supportive care are improving disease management and outcomes. Moreover, rising investments in orphan drug development and favorable regulations are further supporting this market expansion. Metabolic disorders, such as methylmalonic acidemia (MMA), disrupt the body's ability to properly break down certain proteins and fats. This results in an accumulation of methylmalonic acid in the bloodstream. MMA is an inherited condition, classified as an "inborn error of metabolism," that is passed down through families. Symptoms of methylmalonic acidemia can manifest early in infancy and vary in ... Continue reading →

According to FutureWise analysis, the mHealth market in 2026 is US$67.43 billion and is expected to reach US$165.29 billion by 2036, at a CAGR of 9.38%.  The global mHealth market is experiencing significant growth, driven by increased smartphone usage, the rising popularity of wearable health devices, and a growing demand for remote patient monitoring solutions. The COVID-19 pandemic has further accelerated this trend, highlighting the importance of digital health services, including telemedicine and mobile health applications, in contemporary healthcare delivery. Currently, North America is at the forefront of this evolving market, benefiting from a robust healthcare infrastructure and a population that is highly informed about the advantages of digital health technologies. Meanwhile, the Asia-Pacific region is expected to witness rapid expansion due to improved internet connectivity and government initiatives aimed at promoting digital health solutions.Key segments ... Continue reading →

According to FutureWise analysis the market for mHealth Apps in 2026 is US$ 52.19 billion, and is expected to reach US$ 134.50 billion by 2036 at a CAGR of 9.93%. This growth is fueled by rising smartphone use, greater remote patient monitoring adoption, and demand for personalized healthcare solutions. mHealth apps are vital for improving patient engagement, chronic disease management, and access to care, particularly in emerging markets and underserved areas. Mobile health (mHealth) applications have become a significant component of the digital healthcare landscape, transforming the delivery, accessibility, and management of healthcare services. These applications utilize smartphones, tablets, and wearable devices to facilitate a broad spectrum of health-related activities, such as disease prevention, diagnosis, treatment adherence, fitness monitoring, mental health support, and remote patient tracking. By empowering users with healthcare tools, mHealth apps are effectively ... Continue reading →

According to FutureWise analysis the market for Mice Model in 2026 is US$ 1.69 billion, and is expected to reach US$ 4.73 billion by 2036 at a CAGR of 10.84%. The growth in the use of genetically engineered and humanized mouse models is driven by their role in drug discovery, oncology research, and precision medicine. These models are essential for preclinical research, providing insights into disease mechanisms and therapeutic efficacy. Mice models are essential in biomedical research, serving as one of the most prominent experimental systems for investigating human diseases and testing potential therapies. Their close genetic, biological, and physiological similarities to humans make them an effective tool for exploring disease mechanisms, gene functions, and treatment responses. Advances in genetic engineering have further enhanced the utility of mouse models, allowing researchers to accurately replicate complex human diseases. One significant advantage of mice models is their ... Continue reading →

According to FutureWise analysis, the mhealth services market in 2026 is US$151.16 billion, and is expected to reach US$494.22 billion by 2036 at a CAGR of 12.58%.  The global market for mHealth services is experiencing significant growth. This expansion is primarily driven by the increasing integration of mobile technologies into healthcare delivery systems and the shift towards patient-centered care models. Among the fastest-growing segments are teleconsultation services, remote patient monitoring, and chronic disease management, which are fueled by aging populations and the rising prevalence of lifestyle-related diseases. Healthcare providers are increasingly adopting mHealth platforms to reduce operational costs, enhance patient engagement, and improve clinical outcomes through real-time data analytics. Additionally, advancements in 5G technology, artificial intelligence, and cloud computing are further propelling this market by enabling more sophisticated and seamless health ... Continue reading →

According to FutureWise analysis the market for Micro Computed Tomography in 2026 is US$ 0.31 billion, and is expected to reach US$ 0.58 billion by 2036 at a CAGR of 6.46%. This growth is driven by increased use of high-resolution, non-destructive imaging in preclinical research, material science, and industrial inspection. Micro-CT systems provide detailed 3D visualization of internal microstructures, making them crucial in life sciences, orthopedics, and advanced research. Micro-computed tomography (micro-CT) offers several significant advantages in imaging techniques, primarily due to its use of a very narrow bandwidth monochromatic X-ray. This technology utilizes nearly parallel beams of X-rays, which facilitate rapid scanning while allowing for thorough and detailed exploration of samples. One of the standout features of micro-CT is its high spatial resolution, which is crucial for visualizing intricate structures at a micron scale. This high level of detail is particularly ... Continue reading →

According to FutureWise analysis the market for Micro Guide Catheters in 2026 is US$ 0.54 billion, and is expected to reach US$ 0.97 billion by 2036 at a CAGR of 6.03%. The growth is driven by the rising use of minimally invasive procedures in interventional cardiology, neurology, and peripheral vascular interventions. Micro guide catheters enhance precision, aid navigation, and improve outcomes, increasing their demand in advanced healthcare settings. Catheters are specialized medical devices, designed as thin tubes for various therapeutic purposes. These devices can be inserted into different bodily cavities to deliver fluids, medications, and gases, playing a critical role in the treatment of a range of conditions, including neurological, gastrointestinal, ophthalmic, urological, and cardiovascular diseases. Commonly made from polymers such as silicone rubber, polyurethane, polyethylene terephthalate, latex, nylon, and thermoplastic elastomers, silicone stands out due to its inert ... Continue reading →